![]() |
|
|
|||||||
|
|
LinkBack | Thread Tools | Display Modes |
|
|||
|
Exelixis, Inc. today reported preliminary data from a cohort of heavily pretreated patients with metastatic refractory renal cell carcinoma participating in an ongoing phase 1b trial of cabozantinib.
|
| Thread Tools | |
| Display Modes | |
|
|